CCM
AVDL

Cupps Capital Management’s Avadel Pharmaceuticals AVDL Stock Holding History

Cupps Capital Management’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-7,625
Closed -$130K – 218
2014
Q4 		$130K Buy
+7,625
New +$109K 0.01% 179

Other funds holding AVDL

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Cupps Capital Management's AVDL Position: Q1 2015 in Review

Cupps Capital Management sold out of Avadel Pharmaceuticals (AVDL) in Q1 2015, closing a stake of 7,625 shares — an estimated $130K sold.

Cupps Capital Management first reported a position in AVDL in Q4 2014 and held it in 1 quarter. The position peaked at $130K in Q4 2014. 84 funds tracked by Wall St. Rank hold AVDL as of Q1 2015.

  • Cupps Capital Management reported no remaining Avadel Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Cupps Capital Management sold 7,625 Avadel Pharmaceuticals shares in Q1 2015, an estimated $130K.
  • Cupps Capital Management first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 1 quarter.
  • Cupps Capital Management's Avadel Pharmaceuticals position peaked at $130K in Q4 2014.
  • 84 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2015.

Based on Cupps Capital Management's 13F filing for Q1 2015, filed 13 May 2015.